OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Atrash on the Evolution of BCMA-Directed Therapies in Multiple Myeloma

October 17th 2022

Shebli Atrash, MD, discusses the development and current use of BCMA-targeted antibody-drug conjugates and CAR T-cell therapies for the treatment of patients with multiple myeloma.

Dr. Xu on Future Developments in Kidney Cancer

October 17th 2022

Wenxin Xu, MD, discusses future considerations for the treatment of patients with kidney cancer.

Dr. Goy on Discrepancies in Clinical Trial vs Real-World MCL Treatment

October 17th 2022

Andre H. Goy, MD, discusses clinical trial vs real-world treatments in patients with mantle cell lymphoma.

Dr. Bhalla on Unmet Needs in the Treatment of EGFR Exon 20–Mutant NSCLC

October 17th 2022

Sheena Bhalla, MD, discusses the need for improved understanding of EGFR exon 20 insertion mutations in the development of non–small cell lung cancer treatment.

Dr. Strickler on the Benefit of Combining Tucatinib With Trastuzumab in HER2+ CRC

October 14th 2022

John H. Strickler, MD, discusses the benefit of combining tucatinib with trastuzumab in HER2-positive metastatic colorectal cancer.

Dr. Shore on Future Clinical Research Focuses in Prostate Cancer

October 14th 2022

Neal Shore MD, FACS, discusses future clinical research focuses in prostate cancer.

Dr. Ryan on the Efficacy of Ibrutinib Plus Obinutuzumab in Relapsed/Refractory CLL

October 14th 2022

Christine Ryan, MD, discusses the significance of data for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Dr. Kalinsky on Chemotherapy for Premenopausal Patients With HR+/HER2- Breast Cancer

October 13th 2022

Kevin Kalinsky, MD, MS, discusses the role of chemotherapy with ovarian function suppression and hormonal therapy for premenopausal patients with HR–positive/HER2-negative breast cancer.

Dr. Yorio on Treatment Combinations in BRAF-Mutated Melanoma

October 13th 2022

Jeff Yorio, MD, discusses treatment combinations in BRAF-mutated melanoma.

Dr. Shroff on Remaining Unmet Needs for Patients With HCC

October 11th 2022

Rachna T. Shroff, MD, MS, discusses remaining unmet needs for patients with hepatocellular carcinoma.

Dr. Kim on the Evolution of Frontline Treatment in HCC

October 11th 2022

Richard Kim, MD, discusses the evolution of frontline treatment in hepatocellular carcinoma.

Dr. Ali on Key Findings From the Phase 1 Study of Selinexor Plus Ruxolitinib in Myelofibrosis

October 11th 2022

Haris Ali, MD, discusses a phase 1 dose-escalation trial investigating the administration of selinexor in combination with ruxolitinib for patients with treatment-naïve myelofibrosis.

Dr. González-Martín on Updated PFS Data From the PRIMA Trial in Advanced Ovarian Cancer

October 11th 2022

Antonio Gonzalez-Martin, MD, PhD, discusses new long-term progression-free survival data from the phase 3 PRIMA trial in advanced ovarian cancer.

Dr. Kruse on the Effects of the MAINTAIN Trial on HR+/HER2- Breast Cancer Treatment

October 11th 2022

Megan Kruse, MD, discusses the real-world effects of the phase 2 MAINTAIN trial on treatment in advanced hormone receptor–positive, HER2-negative breast cancer.

Dr. Hewitt on Considerations for Conservation Vs Mastectomy in Breast Cancer

October 11th 2022

Kelly Hewitt, MD, discusses treatment considerations for breast conservation vs mastectomy in breast cancer.

Dr. Danilov on the Next Steps for Researching Noncovalent BTK Inhibitors in MCL

October 11th 2022

Alexey V. Danilov, MD, PhD, discusses the next steps for researching noncovalent BTK inhibitors in mantle cell lymphoma.

Dr. Pinilla-Ibarz on the Benefit of BTK Inhibitors in CLL

October 11th 2022

Javier Pinilla-Ibarz, MD, PhD, discusses the benefit of utilizing BTK inhibitors in chronic lymphocytic leukemia.

Dr. Schram on the Efficacy of RLY-4008 in FGFR2+ Cholangiocarcinoma

October 10th 2022

Alison Schram, MD, discusses the efficacy and safety of RLY-4008 in patients with cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

Dr. Kadia on E-selectin as a Target in the Treatment of AML

October 10th 2022

Tapan M. Kadia, MD, discusses the use of E-selectin as a target for treatment in acute myeloid leukemia.

Dr. Cohen on AEs Associated with BTK Inhibitors in CLL

October 7th 2022

Jonathon B. Cohen, MD, MS, discusses the adverse effects associated with BTK inhibitors in chronic lymphocytic leukemia.